Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy, tolerability, and safety of brexpiprazole as adjunctive therapy to antidepressant treatments (ADTs) in adults with major depressive disorder (as defined by DSM-IV-TR criteria) and inadequate response to ADTs. METHOD: Patients with historical inadequate response to 1-3 ADTs were enrolled. All patients entered a prospective 8-week phase on physician-determined, open-label ADT. Those with inadequate response were randomized to ADT + brexpiprazole 2 mg/d or ADT + placebo for 6 weeks. The study was conducted between July 2011 and May 2013. The primary efficacy end point was change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The key secondary end point was change from baseline to week 6 in Sheehan Disability Scale (SDS) mean score. The efficacy population comprised all patients who had ≥ 1 dose of study drug in the double-blind phase and both baseline and ≥ 1 postrandomization MADRS scores. The efficacy population per final protocol included patients from the efficacy population who met amended randomization criteria of inadequate response throughout prospective treatment. RESULTS: Brexpiprazole (n = 175) reduced mean MADRS total score versus placebo (n = 178) at week 6 in the efficacy population per final protocol (-8.36 vs -5.15, P = .0002). Brexpiprazole improved SDS mean score versus placebo (-1.35 vs -0.89, P = .0349). The most common treatment-related adverse events were weight gain (brexpiprazole, 8.0%; placebo, 3.1%) and akathisia (7.4% vs 1.0%). CONCLUSIONS: Adjunctive brexpiprazole therapy demonstrated efficacy and was well tolerated in patients with major depressive disorder and inadequate response to ADTs. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01360645.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Cited by
Items 101–182 of 182
Desai, U. S., Kirson, N. Y., Guglielmo, A., Le, H. H., Spittle, T., Tseng-Tham, J., Shawi, M., & Sheehan, J. J. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0276 · Cited by 15
Yao, Z., & McCall, W. V. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00467-x · Cited by 17
“(iii) An augmentation study in patients with MDD excluded “serious risk of suicide”, no suicidal behaviors were reported on C-SSRS and 7 patients reported worsening SI (not clear how many had SI at baseline) [15].”
BackgroundUpdate on schizophrenia and bipolar disorder: focus on cariprazine
El‐Mallakh, R. S., Findlay, L., El-Mallakh, P. L., & Roberts, R. J. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s97616 · Cited by 13
“Brexpiprazole, which is a partial agonist antipsychotic drug recently approved as an adjunct for the treatment of unipolar depression, appeared to have a therapeutic window – in which 2 mg/day was more effective than both 1 mg and 3 mg daily.(46,47) Thus, the observation that 1.”
Brexpiprazole in the Treatment of Major Depressive Disorder
Shirawi, M. I. A., Edgar, N. E., & Kennedy, S. H. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17731801 · Cited by 12
Pessina, E., Martini, A., Raffone, F., & Martiadis, V. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1299368 · Cited by 12
Tandon, T. R., & Bruijnzeel, D. M. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s85089 · Cited by 14
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
Sussman, M., Yu, J., Kamat, S., Hartry, A., Legacy, S. N., Duffy, R. A., & Aigbogun, M. S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.006 · Cited by 11
Katzman, M. A., Therrien, F., MacKenzie, E. M., Wang, F., de Jong-Laird, A., & Boucher, M. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.021 · Cited by 12
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Isogai, Y., Sekine, D., Aoki, K., Koga, N., et al. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13615 · Cited by 12
Qi, F., Tian, L., Diao, H., Zhao, S., Li, F., Zhang, Y., Qu, M., & Zhang, X. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119435 · Cited by 12
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level
Guizzaro, L., Morgan, D. D. V., Falco, A., & Gallo, C. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.022 · Cited by 11
Ma, M., Ren, Q., Fujita, Y., Yang, C., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4700-z · Cited by 11
“Phase 3 randomized, placebo-controlled studies have demonstrated that brexpiprazole has beneficial effects in patients with inadequate responses to antidepressants (Thase et al. 2015a, 2015b).”
BackgroundImportance of achieving rapid treatment response in major depressive disorder
Alva, G. (2023) · CNS Spectrums · doi:10.1017/s1092852923002213 · Cited by 12
“24,25 Quetiapine is a norepinephrine reuptake inhibitor antipsychotic used as an adjunct to SOC ADTs that also demonstrates rapid and sustained benefits, but is associated with side effects (eg, weight gain) that may be treatment limiting.”
BackgroundMcIntyre, R. S., Bubolic, S., Zhang, Z., MacKenzie, E. M., Therrien, F., Miguelez, M., & Boucher, M. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001825 · Cited by 11
Stroud, J., Cummings, J. L., Chumki, S. R., Such, P., Wang, D., Palma, A. M., Zhang, Z., Brubaker, M., & Grossberg, G. T. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2552278 · Cited by 11
“…brexpiprazole is efficacious as monotherapy for agitation associated with dementia due to Alzheimer’s disease 15,16 , randomized trials in major depressive disorder show that brexpiprazole added to antidepressant has greater efficacy on depressive symptoms than antidepressant monotherapy 38–41 .”
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
Correll, C. U., Ismail, Z., McIntyre, R. S., Rafeyan, R., & Thase, M. E. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.lu21112ah3 · Cited by 11
Self-citationWang, J., Li, W., Li, M., Wu, H.-B., & Qiu, Z.-K. (2023) · Medicine · doi:10.1097/md.0000000000034670 · Cited by 12
Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
Mucci, F., Arone, A., Gurrieri, R., Weiss, F., Russomanno, G., & Marazziti, D. (2025) · Life · doi:10.3390/life15030391 · Cited by 17
Durgam, S., Earley, W. R., Kozauer, S. G., Mo, Y., Lakkis, H. D., Edwards, J. B., Kornstein, S. G., & Fava, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250292 · Cited by 10
Therrien, F., Ward, C., Chokka, P. R., Habert, J., Ismail, Z., McIntyre, R. S., & MacKenzie, E. M. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241233965 · Cited by 9
“…of fi ndings may be limited by the exclusion of patients with certain psychiatric comorbidities and suicidality (although enrolment had fewer restrictions than the Phase 3 randomized studies of adjunctive brexpiprazole 10 – 13 ), and because all trial sites were in a single country (Canada).”
BackgroundTreatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 8
Catalano, G., Robeel, R., Cheney, G. A., Spurling, B. C., Catalano, M. C., Schultz, S. K., & Sanchez, D. L. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001236 · Cited by 12
“Data from these studies noted that doses of lithium higher than 600 mg per day were necessary to achieve antidepressant augmentation response in TRD.”
BackgroundInfluentialThase, M. E. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150041 · Cited by 8
Self-citationBrubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s501207 · Cited by 7
“Thus, preclinical studies support evidence from randomized clinical trials for the antidepressant effects of adjunctive brexpiprazole in MDD, 3–6 and the efficacy of brexpiprazole in combination with the SSRI, sertraline, in PTSD. 9,10 Furthermore, the preclinical evidence from this review highlights the value of this…”
InfluentialMcIntyre, R. S., Stahl, S. M., Shim, S. R., Pompili, M., Goldberg, J. F., Correll, C. U., Kwan, A. T. H., Dri, C. E., Xu, H., Vinberg, M., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0658 · Cited by 12
McIntyre, R. S., Therrien, F., Ismail, Z., Meehan, S. R., Miguelez, M., Larsen, K. G., Chen, D., MacKenzie, E. M., & Thase, M. E. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.04.012 · Cited by 10
Self-citationKrystal, A. D., Mittoux, A., Lindstén, A., & Baker, R. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.026 · Cited by 8
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Kinslow, C. J., Shapiro, S. D., Grunebaum, M. F., & Miller, E. C. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.07.023 · Cited by 7
McIntyre, R. S., Sundararajan, K., Behl, S., Hefting, N., Jin, N., Brewer, C., Hobart, M., & Thase, M. E. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.32 · Cited by 9
“The efficacy, safety, and tolerability of adjunctive brexpiprazole for the short-term treatment of MDD have been demonstrated in four 6-week Phase 3 randomised controlled trials (Thase et al ., 2015a; Thase et al ., 2015b; Hobart et al ., 2018a; Hobart et al ., 2018b).”
Self-citationTerao, I., & Kodama, W. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001862 · Cited by 7
Crump, C., Abuelazm, H., Ibrahim, K., Shah, S. R., & El‐Mallakh, R. S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367695 · Cited by 7
“This is perhaps best seen in its efficacy as an adjunct in treatment-resistant unipolar depression [31–35] including significant improvements in function [35,36].”
Brexpiprazole as a new approach of treatment in somatization disorder
Chiappini, S., Mosca, A., Martinotti, G., Carlo, F. D., Miuli, A., Dattoli, L., Pettorruso, M., & Giannantonio, M. D. (2022) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2022.100031 · Cited by 6
Seetasith, A., Greene, M., Hartry, A., & Burudpakdee, C. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s220007 · Cited by 6
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 8
Zemach, S., Zohar, J., Correll, C. U., Stahl, S. M., Drago, F., Goodwin, G. M., Möller, H., Uchida, H., Siafis, S., Santos, M., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00338-4 · Cited by 7
Kishi, T., Sakuma, K., Saito, T., Nakagawa, A., Kato, M., & Iwata, N. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12414 · Cited by 7
Carpenter, J. S., Zmicerevska, N., Crouse, J. J., Nichles, A., Garland, A., Song, Y. J. C., Wilson, C. E., Rohleder, C., McHugh, C. M., Leweke, F. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056298 · Cited by 5
Cost-Savings From an Antipsychotic Tablet-Splitting Program.
Carey, H., & Fondriest, M. (2017) · PubMed Central · Cited by 7
Brexpiprazole versus placebo or other antidepressive agents for treating depression
Ralovska, S., Koychev, I. G., Marinov, P., Furukawa, T. A., Mulsant, B. H., & Cipriani, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013866.pub2 · Cited by 4
Newcomer, J. W., Meehan, S. R., Chen, D., Brubaker, M., & Weiss, C. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m14786 · Cited by 6
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Sekine, D., Aoki, K., Shiomi, Y., & Higuchi, T. (2024) · CNS Drugs · doi:10.1007/s40263-024-01124-w · Cited by 5
Brexpiprazole: a step forward for precision medicine in resistant depression
Serretti, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528233 · Cited by 4
“The two previous studies on the basis of which the drug was approved as adjunctive treatment for depression [5,6] indeed needed a further confirmation.”
ResultCorrell, C. U., Mafi, C. E., Fagiolini, A. M., Seerden, P., Seifritz, E., Tiihonen, J., Vita, A., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s539306 · Cited by 5
“56 Notably, however, the approved brexpiprazole doses to treat depression are lower (2–3 mg/d) than for schizophrenia (2–4 mg/d), with higher doses of brexpiprazole being particularly beneficial for positive symptom control.”
InfluentialFowler, J. C., Skubiak, T., Engelhardt, K., Furst, B. A., Zhao, S. J., Nyilas, M., Profit, D., & Carson, W. H. (2021) · Journal of Scientific Innovation in Medicine · doi:10.29024/jsim.84 · Cited by 3
Self-citationMedication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 5
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
“A total of 12 trials were included: two aripiprazole studies, 28,29 two brexpiprazole studies, 30,31 four olanzapine plus fluoxetine studies, 32–34 two quetiapine studies, 35,36 and two ESK-NS studies.”
Amada, N., Sato, S., Ishikawa, D., Nakamura, M., Suzuki, M., Futamura, T., & Maeda, K. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12461 · Cited by 4
Ardic, F. C., Zhang, Z., & Hogan, M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1618176 · Cited by 4
Atypical Antipsychotics in Major Depressive Disorder
Orsolini, L., Vellante, F., Valchera, A., Fornaro, M., Carano, A., Pompili, M., Perna, G., Serafini, G., Nicola, M. D., Martinotti, G., et al. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_18 · Cited by 3
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Boskovic, D. H., Huang, D., Severtson, S. G., Marci, C. D., Awasthi, S., Ardic, F. C., Eisenberg, D. F., & Kapadia, S. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01027-6 · Cited by 2
Mok, Y. M., Tan, P. L. L., Bose, R., Herr, K. J., & Ung, E. K. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1143 · Cited by 4
Rothman, B., Brewer, C., Chang, D., Hobart, M., Hefting, N., McQuade, R. D., & Grant, J. E. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.31 · Cited by 4
“Brexpiprazole had a similar safety profile in BPD to that established in schizophrenia and MDD (Marder et al ., 2017; Thase et al ., 2019).”
InfluentialSelf-citationNew Treatment Options for Depression: A Primer for Internists
Byun, T. H., Chaliki, S. S., & Poole, K. G. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.012 · Cited by 4
The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
Kikuchi, T., Maeda, K., Yamada, S., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_424-1 · Cited by 2
Self-citationPhilippi, R., & Correa, R. (2022) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272022000300337 · Cited by 2
“En otras palabras, el brexpiprazol en combinación con un antidepresivo mostró una eficacia equivalente en comparación con aripiprazol o quetiapina (NNT = 11); además, brexipiprazol más antidepresivo se asoció con menos acatisia (en comparación con aripiprazol) y menos somnolencia / aumento de peso (en comparación con…”
BackgroundWhen an Antipsychotic Working as an Antidepressant, Do They Have a Therapeutic Window?
Aydın, İ. H., Salifu, A., Settle, K., & El‐Mallakh, R. S. (2025) · Annals of Clinical Psychiatry · doi:10.1177/10401237251344096 · Cited by 2
Khalid, R., Elbashir, G., Hassan, A., & Abdulbagi, M. (2026) · Cureus · doi:10.7759/cureus.109712 · Cited by 1
Research Progress of the Antidepressants Targeting the Monomine Receptors and Glutamate System
任, 莹. (2016) · Pharmacy Information · doi:10.12677/pi.2016.52007 · Cited by 1
The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
Kikuchi, T., Maeda, K., Yamada, S., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_424 · Cited by 1
Self-citationFasipe, O. J., & Ogunboye, I. (2024) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqae017 · Cited by 9
González, J. M., Townsend, M., Waters, H. C., Brubaker, M., Wallace, M., & Johnson, F. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309562 · Cited by 2
Therrien, F., Chokka, P. R., Habert, J., Ismail, Z., McIntyre, R. S., Dine, J. L., Brown, T. M., Zhang, Z., MacKenzie, E. M., & Ward, C. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2558140 · Cited by 1
“Brexpiprazole, which acts on the serotonergic, dopaminergic, and noradrenergic systems, has demonstrated efficacy as an adjunctive treatment in patients with MDD and inadequate response to ADT 17–21 .”
InfluentialMuneer, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_2 · Cited by 2
Research Progress of the Antidepressants Targeting the Monomine Receptors and Glutamate System
Ren, Y., Zhou, L., Wu, H., Shang, J., & Jiangsu, N. (2016)
Chue, P. S., & Chue, J. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.004 · Cited by 1
Herman, A. (2017) · uO Research (University of Ottawa) · doi:10.20381/ruor-20993 · Cited by 1
“…which have both been approved for use in schizophrenia and bipolar disorder, but their effects at α2-adrenoceptors may help improve mood regulation within these disorders, and potentially also in MDD (Keitner et al, 2009, Dhir and Kulkarni et al, 2008; Oosterhoff et al, 2016; Thase et al, 2015).”
BackgroundKirby, J. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-21514 · Cited by 1
“Among them, two multicenter, randomized, double-blind, placebo-controlled trials support the use of brexpiprazole as an effective agent over placebo in treatment-resistant MDD (Thase et al., 2015a; 2015b).”
Kopeček, M. (2019) · Praktické lékárenství · doi:10.36290/lek.2019.023
Ontiveros, J. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82568
“Also, the use of brexpiprazole has been suggested if aripiprazole generates akathisia [88, 89].”
Chapter 30. Aripiprazole and Brexpiprazole
Birze, N., Yuan, C., & Garcia-Pittman, E. C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as30
Chapter 4. Antipsychotic Drugs
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd04
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Gareayaghi, A., Şişman, E., Türksoy, M., & Polat, A. (2025) · Acta Medica Nicomedia · doi:10.53446/actamednicomedia.1621458
Kapadia, S., Zhang, Z., Csoboth, C. T., Patel, M., Thase, M. E., & Papakostas, G. I. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf050
Self-citationMaruoka, J., Kozuka, K., Egami, R., Kubo, Y., Kakumoto, Y., Kikuchi, T., & Kume, K. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag007 · Cited by 1
Hu, K., Lo, C. W. H., Awasthi, S., Pain, O., Singh, M., Ahn, Y., Aitchison, K. J., Baune, B. T., Biernacka, J. M., Bondolfi, G., et al. (2026) · medRxiv · doi:10.64898/2026.06.03.26354703 · Cited by 1
Cutler, A. J., Lemyre, A., Zhang, Q., Mao, C., Totev, T. I., Gauthier‐Loiselle, M., Wu, Y., Liu, J., Hashim, M., Namjoshi, M., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03630-3
“Two trials were available for each treatment: NCT00095823 [15] and NCT00095758 [14] for ari‑ piprazole, NCT01360645 [10] and NCT01360632 [11] for brexpiprazole, NCT03738215 [8] and NCT01469377 [9] for cariprazine, NCT04985942 [28] and NCT05061706 [29] for lumateperone, and NCT00326105 [12] and…”
Taylor, J. D., Rolan, P. E., Jaros, M., Harrison, J., Ratcliffe, S. H., Berk, M., & Hilt, D. C. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10689
“33 Considering these effect sizes, the findings in the current trial of ‘ difficult-to-treat ’ patients with moderately severe MDD could be regarded as a signal of potential clinical relevance.”
Gill, N., Sohi, S. K., Bhatti, N., Joseph, G., & Abhilasha, P. (2026) · Cureus · doi:10.7759/cureus.117032
“In the PYXIS trial, adjunctive brexpiprazole 2 mg was separated from adjunctive placebo on the Montgomery-Åsberg Depression Rating Scale (MADRS) [20].”
Severtson, S. G., Boskovic, D. H., Eisenberg, D. F., Ardic, F. C., Abdrabboh, A., & Marci, C. D. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01028-5
Metadata
- Authors
- Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., & Eriksson, H.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Thase, Michael E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2015-09-23
- Volume
- 76
- Issue
- 09
- Pages
- 1224-1231
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1868790909
- Cited by
- 182
- References
- 39
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 17 · 2017: 20 · 2016: 24 · 2015: 6
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- brexpiprazole, major depressive disorder, adjunctive therapy, antidepressant response, inadequate response to antidepressants, atypical antipsychotics, treatment-resistant depression, weight gain, akathisia, tolerability, functional disability
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Thiophenes, Antipsychotic Agents, Quinolones, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.